1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014’, provides an overview of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Skin And Skin Structure Infections (SSSI) Caused By Bacteria
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2014
Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Overview 6
Therapeutics Development 7
Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Overview 7
Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis 8
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics under Development by Companies 9
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Products under Development by Companies 13
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Companies Involved in Therapeutics Development 14
Furiex Pharmaceuticals, Inc. 14
Nabriva Therapeutics AG 15
Tetraphase Pharmaceuticals Inc. 16
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
acorafloxacin - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
BC-3781 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
eravacycline - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
IOG-101 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Nu-2 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
siderocillin - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Small Molecules to Inhibit 23S Ribosomal RNA for Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Recent Pipeline Updates 37
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables

Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2014 7
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Clinical Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Comparative Analysis by Unknown Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Furiex Pharmaceuticals, Inc., H2 2014 14
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Nabriva Therapeutics AG, H2 2014 15
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2014 16
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 23
Number of Products by Stage and Molecule Type, H2 2014 25
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics - Recent Pipeline Updates, H2 2014 37
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Dormant Projects, H2 2014 42

List of Figures

Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H2 2014 7
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Assessment by Monotherapy Products, H2 2014 17
Number of Products by Top 10 Targets, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Top 10 Routes of Administration, H2 2014 22
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 23
Number of Products by Top 10 Molecule Types, H2 2014 24
Number of Products by Stage and Top 10 Molecule Types, H2 2014 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

Animal Antibiotics and Antimicrobials Market by Product, Mode of Delivery, Animal - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global animal antibiotics and antimicrobials market is estimated to grow at a CAGR of 4.6% from 2016 to 2021, to reach USD 4.73 billion by 2021 from USD 3.77 billion in 2016. The growth of this market ...

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance

  • $ 4995
  • Industry report
  • January 2017
  • by GBI Research

Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance Summary The antibacterial drug market covers ...

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight’s Methicillin-resistant Staphylococcus aureus (MRSA) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the ...

Global Feed Antibiotics Market

December 2016 $ 4250

Acetic Acid Markets In China

January 2017 $ 4000

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.